Phase I study of gemcitabine using a once every 2 weeks schedule
- 1 December 1997
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 76 (11) , 1489-1493
- https://doi.org/10.1038/bjc.1997.583
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II studyEuropean Journal Of Cancer, 1996
- Phase II study of gemcitabine in patients with advanced pancreatic cancerBritish Journal of Cancer, 1996
- Advanced breast cancer: a phase II trial with gemcitabine.Journal of Clinical Oncology, 1995
- Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive daysEuropean Journal Of Cancer, 1994
- Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cAnnals of Oncology, 1994
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI Journal of the National Cancer Institute, 1994
- Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.Journal of Clinical Oncology, 1994
- Difluorodeoxycytidine (dFdC) — gemcitabine: A phase I studyInvestigational New Drugs, 1992
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991
- Cytotoxicity and Antitumor Activity of 2′,2′-Difluorodeoxycytidine (Gemcitabine)Cancer Investigation, 1990